- Home
- CYBR vs ICLR Comparison
CYBR vs ICLR Comparison
Compare CYBR & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBR
- ICLR
- Stock Information
- Founded
- CYBR 1999
- ICLR 1990
- Country
- CYBR Israel
- ICLR Ireland
- Employees
- CYBR N/A
- ICLR N/A
- Industry
- CYBR Computer Software: Prepackaged Software
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- Sector
- CYBR Technology
- ICLR Health Care
- Exchange
- CYBR Nasdaq
- ICLR Nasdaq
- Market Cap
- CYBR 17.7B
- ICLR 16.4B
- IPO Year
- CYBR 2014
- ICLR 1998
- Fundamental
- Price
- CYBR $383.29
- ICLR $201.39
- Analyst Decision
- CYBR Strong Buy
- ICLR Strong Buy
- Analyst Count
- CYBR 30
- ICLR 12
- Target Price
- CYBR $394.67
- ICLR $278.27
- AVG Volume (30 Days)
- CYBR 634.6K
- ICLR 913.3K
- Earning Date
- CYBR 02-13-2025
- ICLR 02-19-2025
- Dividend Yield
- CYBR N/A
- ICLR N/A
- EPS Growth
- CYBR N/A
- ICLR 28.78
- EPS
- CYBR N/A
- ICLR 9.53
- Revenue
- CYBR $1,000,742,000.00
- ICLR $8,281,675,999.00
- Revenue This Year
- CYBR $33.00
- ICLR $4.00
- Revenue Next Year
- CYBR $18.93
- ICLR $1.37
- P/E Ratio
- CYBR N/A
- ICLR $21.18
- Revenue Growth
- CYBR 33.10
- ICLR 1.99
- 52 Week Low
- CYBR $223.41
- ICLR $181.51
- 52 Week High
- CYBR $421.00
- ICLR $347.72
- Technical
- Relative Strength Index (RSI)
- CYBR 53.26
- ICLR 54.92
- Support Level
- CYBR $372.02
- ICLR $181.51
- Resistance Level
- CYBR $421.00
- ICLR $203.26
- Average True Range (ATR)
- CYBR 13.86
- ICLR 6.32
- MACD
- CYBR -0.69
- ICLR 1.50
- Stochastic Oscillator
- CYBR 37.57
- ICLR 72.45
About CYBR CyberArk Software Ltd.
CyberArk is a cybersecurity vendor focused on the identity market. The company's core privileged access management offering is a market leader within that subsegment, with more than half of the Fortune 500 CyberArk customers. The identity security vendor was founded in 1999 and has around 9,000 customers across various industries. While historically, CyberArk has sold its security solutions primarily via on-premises licenses, over the past few years, it has transitioned to a subscription, recurring revenue model.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.